📊 PURE Key Takeaways
Is Pure Bioscience, Inc.. (PURE) a Good Investment?
Pure Bioscience faces existential financial distress with negative stockholders' equity of -$6.3M, indicating technical insolvency and complete equity wipeout for shareholders. The company exhibits a critical liquidity crisis (0.25x current ratio), burns $889K annually in free cash flow, and maintains only $198K cash against $7.1M liabilities with stagnant revenue, leaving minimal operational runway.
Why Buy Pure Bioscience, Inc.. Stock? PURE Key Strengths
- Gross margin of 59.8% indicates underlying unit economics are viable if business could scale revenue
- No long-term debt burden simplifies restructuring obligations
- Net loss improved 28.4% YoY suggesting modest cost control initiatives underway
PURE Stock Risks: Pure Bioscience, Inc.. Investment Risks
- Negative stockholders' equity of -$6.3M represents technical insolvency with complete equity value destruction
- Severe liquidity crisis with 0.25x current ratio and only $198K cash versus $7.1M total liabilities creates imminent payment default risk
- Negative free cash flow of -$889K and flat revenue (-0.2% YoY) indicate unsustainable burn with no growth catalyst for turnaround
- Operating margin of -92.3% demonstrates business generates massive losses relative to revenue scale
Key Metrics to Watch
- Quarterly cash burn rate and months of cash runway remaining
- Revenue stabilization and gross profit absolute dollars
- Short-term liability maturity schedule and refinancing ability
Pure Bioscience, Inc.. (PURE) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
PURE Profit Margin, ROE & Profitability Analysis
PURE vs Materials Sector: How Pure Bioscience, Inc.. Compares
How Pure Bioscience, Inc.. compares to Materials sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Pure Bioscience, Inc.. Stock Overvalued? PURE Valuation Analysis 2026
Based on fundamental analysis, Pure Bioscience, Inc.. has mixed fundamental signals relative to the Materials sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Pure Bioscience, Inc.. Balance Sheet: PURE Debt, Cash & Liquidity
PURE Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Pure Bioscience, Inc..'s revenue has declined by 68% over the 5-year period, indicating business contraction. The most recent EPS of $-0.03 indicates the company is currently unprofitable.
PURE Revenue Growth, EPS Growth & YoY Performance
PURE Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $391.0K | -$785.0K | $-0.01 |
| Q1 2026 | $556.0K | -$464.0K | $0.00 |
| Q3 2025 | $441.0K | -$580.0K | $-0.01 |
| Q2 2025 | $326.0K | -$798.0K | $-0.01 |
| Q1 2025 | $556.0K | -$689.0K | $-0.01 |
| Q3 2024 | $407.0K | -$857.0K | $-0.01 |
| Q2 2024 | $326.0K | -$1.0M | $-0.01 |
| Q1 2024 | $471.0K | -$735.0K | $-0.01 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Pure Bioscience, Inc.. Dividends, Buybacks & Capital Allocation
PURE SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Pure Bioscience, Inc.. (CIK: 0001006028)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PURE
What is the AI rating for PURE?
Pure Bioscience, Inc.. (PURE) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PURE's key strengths?
Claude: Gross margin of 59.8% indicates underlying unit economics are viable if business could scale revenue. No long-term debt burden simplifies restructuring obligations.
What are the risks of investing in PURE?
Claude: Negative stockholders' equity of -$6.3M represents technical insolvency with complete equity value destruction. Severe liquidity crisis with 0.25x current ratio and only $198K cash versus $7.1M total liabilities creates imminent payment default risk.
What is PURE's revenue and growth?
Pure Bioscience, Inc.. reported revenue of $1.2M.
Does PURE pay dividends?
Pure Bioscience, Inc.. does not currently pay dividends.
Where can I find PURE SEC filings?
Official SEC filings for Pure Bioscience, Inc.. (CIK: 0001006028) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PURE's EPS?
Pure Bioscience, Inc.. has a diluted EPS of $-0.01.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PURE a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Pure Bioscience, Inc.. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is PURE stock overvalued or undervalued?
Valuation metrics for PURE: ROE of N/A (sector avg: 14%), net margin of -108.6% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
Should I buy PURE stock in 2026?
Our dual AI analysis gives Pure Bioscience, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PURE's free cash flow?
Pure Bioscience, Inc..'s operating cash flow is $-856.0K, with capital expenditures of $33.0K. FCF margin is -77.3%.
How does PURE compare to other Materials stocks?
Vs Materials sector averages: Net margin -108.6% (avg: 10%), ROE N/A (avg: 14%), current ratio 0.25 (avg: 1.6).